Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several top-sellers. At the end of 2023, Pfizer completed its acquisition of Seagen Inc. (NASDAQ: SGEN), a biotechnology leader in transformative cancer medicines. Although Pfizer still has a few growth best-sellers, migraine therapy Nurtec and respiratory syncytial virus (RSV) vaccine, Pfizer is betting on such
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine Gardasil. However, Merck still recorded a net quarterly loss due to charges that resulted from a
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine Gardasil. However, Merck still recorded a net quarterly loss due to charges that resulted from a deal to co-develop three after-cancer treatments with a Japanese drugmaker Daiichi Sankyo. But, Merck’s patent for Keytruda is expiring in 2028 so it needs more products under its belt. Like its peers, Moderna